多发性硬化的治疗进展

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (5): 499-503.

多发性硬化的治疗进展

张留福¹, 黄琼², 楚兰¹

¹贵阳医学院附属医院神经内科,贵阳 550004,贵州;
²中南大学临床药理研究所,长沙 410078,湖南

收稿日期:2007-04-02 修回日期:2007-05-01 发布日期:2020-10-29
通讯作者: 楚兰,女,教授,硕士生导师,研究方向:神经免疫学。Tel:0851-6855119 E-mail:chulan8999@sina.com
作者简介:张留福,男,硕士,助教,研究方向:神经免疫学。Tel:0851-6855119 E-mail:hfzhangliufu@yahoo.com.cn

Progress in treatment of multiple sclerosis

ZHANG Liu-fu¹, HUANG Qiong², CHU Lan¹

¹Neurology Department of Affiliated Hospital, Guiyang Medical College, Guiyang 550004, Guizhou, China;
²Clinical Pharmacological Institute of Central South University, Changsha 410078, Hunan, China

Received:2007-04-02 Revised:2007-05-01 Published:2020-10-29

摘要/Abstract

摘要： 多发性硬化是发生于中枢神经系统的由免疫介导的慢性自身免疫性脱髓鞘疾病。本病病因不明,可能与病毒感染和自身免疫功能紊乱等有关。其治疗方案仍不十分成熟,本文将主要从免疫干预治疗、基因治疗、干细胞移植治疗和其他治疗等四个方面对该病的治疗进展作一综述。

关键词: 多发性硬化, 免疫干预治疗, 基因治疗, 干细胞移植治疗

Abstract: Multiple sclerosis is a demyelinating disease affecting central nervous system induced by a chronic autoimmune disorder. Its exactly etiological mechanism remains unknown. Viral infection and autoimmunity functional disorder may be one of the reasons. In this article, we mainly reviewed the progress in the treatment of the disease including immune depressant, gene therapy, transplant therapy of stem cells and other therapies.

Key words: multiple sclerosis, immunologic intervention therapy, gene therapy, stem cellular transplant therapy

中图分类号:

R744.5+1

张留福, 黄琼, 楚兰. 多发性硬化的治疗进展[J]. 中国临床药理学与治疗学, 2007, 12(5): 499-503.

ZHANG Liu-fu, HUANG Qiong, CHU Lan. Progress in treatment of multiple sclerosis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(5): 499-503.

参考文献

1 Johnson KP, Blumhardt LD.Practical issues in the management of multiple sclerosis.Introduction[J].Neurology , 2002 ;58:S1-S2.
2 Kreitman RR, Blanchette F. On the horizon:possible neuroprotective role for glatiramer acetate[J].Mult Scler, 2004;10:S81-S86.
3 Flechter S, Vardi J, Pollak L, et al.Comparison of glatiramer acetate ( Copaxone) and interferon beta-1b ( Betaferon) in multiple sclerosis patients:an open-label 2-year follow-up[J].J Neurol Sci, 2002;197:51-55.
4 Khan OA, TselisAC, Kamholz JA, et al.A prospective, openlabel treatment trial to compare the effect of IFN beta-1a( Avonex) , IFN beta-1b ( Betaseron) , and glatiramer acetate( Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis[J].Eur J Neurol, 2001;8:141-148.
5 Ropper AH.Selective treatment of multiple sclerosis[J].N Engl J Med, 2006 ;354:965-967.
6 Wolinsky JS, Narayana PA, O' Connor P, et al.Glatiramer acetate in primary progressive multiple sclerosis:results of a multinational, multicenter, double-blind, placebo-controlled trial [J].Ann Neurol, 2007 ;61:14-24.
7 Kieseier BC, Hartung HP.Current disease-modifying therapies in multiple sclerosis[J].2003 Semin Neurol, 2003;23:133-146.
8 PRISMS Study Group and the University of British ColumbiaMS MRI Analysis Group.PRISMS-4:Long-term efficacy of interferon-beta-1a in relapsing MS[J].Neurology, 2001 ;56:1628-1636.
9 Panitch H, Goodin DS, Francis G, et al.Randomized, comparative study of interferon beta-1a treatment regimens in MS:The EVIDENCE Trial[J].Neurology , 2002;59:1496-1506.
10 Panitch H,Miller A, Paty D, et al.Interferon beta-1b in secondary progressive MS:results from a 3-year controlled study [J].Neurology , 2004 ;63:1788-1795.
11 Cohen BA, Mikol DD.Mitoxantrone treatment of multiple sclerosis: safety considerations[J].Neurology, 2004;63:S28-S32.
12 Edan G,Miller D, Clanet M, et al.Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria[J].J Neurol Neurosurg Psy chiatry, 1997;62: 112-118.
13 Hartung HP, Gonsette R, Konig N, et al.Mitoxantrone in progressive multiple sclerosis:a placebo-controlled, doubleblind, randomised, multicentre trial[J].Lancet, 2002 ;360:2018-2025.
14 Durelli L, Isoardo G.High-dose intravenous immunoglobulin treatment of multiple sclerosis[J].Neurol Sci, 2002;23:S39-S48.
15 Khan OA, Dhib-Jalbut SS.Neutralizing antibodies to interferon beta-1a and interferon beta-1b inMS patients are cross-reactive [J].Neurology , 1998 ;51:1698-1702.
16 Sorensen PS.The role of intravenous immunoglobulin in the treatment of multiple sclerosis[J].J Neurol Sci, 2003;206:123-130.
17 Furlan, R, Pluchino S, Martino G.Gene therapy-mediated modulation of immune processes in the central nervous system [J].Curr Pharm Des, 2003;9:2002-2008.
18 张兴梅, 黄河清, 陈康宁等.基因治疗人类多发性硬化症的可能性研究:腺病毒转染CTLA-4Ig 对动物实验性自身免疫性脑脊髓炎病理过程的抑制或阻断作用[J].中国临床康复, 2004;8:7034-7036.
19 Fassas A, Kimiskidis VK.Stem cell transplantation for multiple sclerosis:what is the evidence[J] ? Blood Rev, 2003;17:233-240.
20 Burt RK, Slavin S, BurnsWH, et al.Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation:getting closer to a cure[J].Blood , 2002 ;99:768-784.
21 Gratwohl A, Passweg J, Bocelli-Tyndall C, et al.Autologous hematopoietic stem cell transplantation for autoimmune diseases [J].Bone Marrow Transplant, 2005 ;35:869-879.
22 董会卿, 徐娟, 谢淑萍, 等.自体外周造血干细胞移植治疗进展型多发性硬化初步研究[J].中华神经科杂志,2004 ;37:11-14.
23 Tyndall A, Daikeler T.Autologous hematopoietic stem cell transplantation for autoimmune diseases[J].Acta Haematol,2005 ;114:239-247.
24 Walker M, Zunt JR, Kraft GH.Brachial neuropathy after immunosuppression and stem cell transplantation for multiple sclerosis[J].Mult Scler, 2005 ;11:90-91.
25 Malfroy B, Doctrow SR, Orr PL, et al.Prevention and suppression of autoimmune encephalomyelitis by EUK28, a synthetic catalytic scavenger of oxygen reactive metabolites[J].Cell Immunol, 1997 ;177:62-68.
26 Liu Y, Zhu B, Wang X, et al.Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis[J].J Neuroimmunol, 2003;139:327-351.
27 Jolivalt CG, Howard RB, Chen LS, et al.A novel nitricoxide scavenger in combination with cyclosporine A ameliorates experimental autoimmune encephalomyelitis progression in mice[J].J Neuroimmunol, 2003;138:56-64.
28 Brundula V, Rewcastle NB, Metz LM, et al.Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis[J].Brain, 2002;125:1297-1308.
29 Metz LM, Zhang Y, Yeung M, et al.Minocycline reduces gadolinium enhancing magnetic resonance imaging lesions in multiple sclerosis[J].Ann Neurol, 2004 ;55:756-757.

[1]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[2]	姜兵兵. microRNA在亨廷顿病中的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(6): 677-685.
[3]	贾建光，郭晨旭，李靖，张立功，王益民，全志伟，钱军. 腺病毒介导的MDA-7/IL-24基因对裸鼠胆囊癌移植瘤的生长抑制和促凋亡作用[J]. 中国临床药理学与治疗学, 2015, 20(11): 1221-1226.
[4]	孙宝，张伟. DNA甲基化在自身免疫性疾病发病机制中作用研究进展[J]. 中国临床药理学与治疗学, 2015, 20(11): 1308-1314.
[5]	李征, 向开敏, 彭淑平, 李桂源. MicroRNA-34用于肿瘤治疗的基础研究[J]. 中国临床药理学与治疗学, 2014, 19(1): 67-73.
[6]	汪祥海, 魏强, 王晓彤, 查林涛, 杨玉雯. 携带人S100A1基因的重组腺相关病毒载体的构建及鉴定[J]. 中国临床药理学与治疗学, 2013, 18(8): 853-857.
[7]	吕颖慧, 龚玉华, 刁勇, 许瑞安, 王启钊. 高迁移率族蛋白A2在肿瘤发生和血管形成中的双重作用[J]. 中国临床药理学与治疗学, 2011, 16(9): 975-980.
[8]	刘慕君, 刘艳平, 刘雄昊. 血友病A的基因治疗[J]. 中国临床药理学与治疗学, 2010, 15(8): 932-937.
[9]	刘扬, 吴金明, 金思思, 申苏建, 吴利敏, 江宏峰, 金颖. 假单胞菌外毒素体外靶向抗肝细胞癌的实验研究[J]. 中国临床药理学与治疗学, 2010, 15(4): 372-375.
[10]	王启钊, 吕颖慧, 许瑞安. 基因治疗用腺相关病毒载体的剂量效应与剂量控制[J]. 中国临床药理学与治疗学, 2008, 13(10): 1182-1194.
[11]	丁娅, 张晓实, 彭瑞清, 张蓉, 张念华, 李志铭, 刘继彦, 马锦, 程霞, 苏义顺, 曾益新. 重组人p53腺病毒注射液治疗晚期实体肿瘤的安全性和近期疗效评价[J]. 中国临床药理学与治疗学, 2005, 10(9): 1025-1029.
[12]	伍远雄, 王晋明, 张美春, 梁远红. β₁受体反义基因治疗对肾性高血压大鼠心脏的保护作用[J]. 中国临床药理学与治疗学, 2005, 10(10): 1123-1127.
[13]	单守杰, 陈绍良. 骨髓干细胞移植治疗缺血性心脏病的研究进展[J]. 中国临床药理学与治疗学, 2002, 7(5): 473-476.
[14]	王洁, 殷彩玲. 戈谢氏病基因治疗的新进展[J]. 中国临床药理学与治疗学, 2002, 7(2): 181-183.